Tian Hong-Xia, Zhang Xu-Chao, Wang Zhen, Chen Jian-Guang, Chen Shi-Liang, Guo Wei-Bang, Wu Yi-Long
Medical Research Center, Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Cancer Biol Med. 2016 Mar;13(1):68-76. doi: 10.28092/j.issn.2095-3941.2015.0094.
This study aims to establish a method for highly parallel multiplexed detection of genetic mutations in Chinese lung cancer samples through Agena iPLEX chemistry and matrix-assisted laser desorption ionization time-of-flight analysis on MassARRAY mass spectrometry platform.
We reviewed the related literature and data on lung cancer treatments. We also identified 99 mutation hot spots in 13 target genes closely related to the pathogenesis, drug resistance, and metastasis of lung cancer. A total of 297 primers, composed of 99 paired forward and reverse amplification primers and 99 matched extension primers, were designed using Assay Design software. The detection method was established by analyzing eight cell lines and six lung cancer specimens. The proposed method was then validated through comparisons by using a LungCarta(TM) kit. The sensitivity and specificity of the proposed method were evaluated by directly sequencing EGFR and KRAS genes in 100 lung cancer cases.
The proposed method was able to detect multiplex genetic mutations in lung cancer cell lines. This finding was consistent with the observations on previously reported mutations. The proposed method can also detect such mutations in clinical lung cancer specimens. This result was consistent with the observations with LungCarta(TM) kit. However, an FGFR2 mutation was detected only through the proposed method. The measured sensitivity and specificity were 100% and 96.3%, respectively.
The proposed MassARRAY technology-based multiplex method can detect genetic mutations in Chinese lung cancer patients. Therefore, the proposed method can be applied to detect mutations in other cancer tissues.
本研究旨在通过Agena iPLEX化学法以及在MassARRAY质谱平台上进行基质辅助激光解吸电离飞行时间分析,建立一种对中国肺癌样本中的基因突变进行高度平行多重检测的方法。
我们查阅了肺癌治疗的相关文献和数据。我们还在与肺癌发病机制、耐药性和转移密切相关的13个靶基因中确定了99个突变热点。使用Assay Design软件设计了总共297条引物,包括99对正向和反向扩增引物以及99条匹配的延伸引物。通过分析8种细胞系和6份肺癌标本建立了检测方法。然后通过使用LungCarta™试剂盒进行比较来验证所提出的方法。通过对100例肺癌病例中的EGFR和KRAS基因进行直接测序,评估了所提出方法的敏感性和特异性。
所提出的方法能够检测肺癌细胞系中的多重基因突变。这一发现与先前报道的突变观察结果一致。所提出的方法还能够在临床肺癌标本中检测到此类突变。这一结果与使用LungCarta™试剂盒的观察结果一致。然而,仅通过所提出的方法检测到了FGFR2突变。测得的敏感性和特异性分别为100%和96.3%。
所提出的基于MassARRAY技术的多重方法能够检测中国肺癌患者的基因突变。因此,所提出的方法可应用于检测其他癌组织中的突变。